Get to know our clinical trials
Phase 3 clinical trial to compare the efficacy and safety of MK-2870 in monotherapy versus physician-choice treatment in participants with endometrial cancer who have received prior chemotherapy.
THE PRIMARY OBJECTIVE IS TO COMPARE MK-2870 WITH PHYSICIAN'S CHOICE TREATMENT (TEM) IN TERMS OF PROGRESSION-FREE SURVIVAL (PFS) ACCORDING TO RECIST 1.1 CRITERIA, BASED ON AN INDEPENDENT BLINDED CENTRAL REVIEW (ICER).
Specialist
Medical Oncology Department
Madrid headquarters
Technical Summary
- PHASE 3, RANDOMIZED, ACTIVE TREATMENT-COMPARATIVE, OPEN-LABEL, MULTICENTER STUDY TO COMPARE THE EFFICACY AND SAFETY OF MK-2870 IN MONOTHERAPY VS. PHYSICIAN-CHOICE TREATMENT IN PARTICIPANTS WITH ENDOMETRIAL CANCER WHO HAVE PREVIOUSLY RECEIVED PLATINUM DERIVATIVE CHEMOTHERAPY AND IMMUNOTHERAPY
- Code EudraCT: 2023-504816-14
- Protocol number: MK-2870-005
- Promoter: Merck Sharp & Dohme, S.A.
- Molecule/Drug: MK-2870
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.